T Cell Immunotherapy in Cancer Treatment

T cell immunotherapy harnesses the specificity and potency of the adaptive immune system to target malignant cells. Central to this approach are strategies that either augment the natural tumour-killing capacity of T lymphocytes or engineer them to recognise cancer-associated antigens. Two principal modalities have emerged: immune checkpoint blockade, which releases inhibitory brakes on endogenous T cells, and adoptive cell transfer, which infuses patients with large numbers of tumour-reactive lymphocytes. Chimeric antigen receptor (CAR) T cells, generated by genetic modification of T cells to express synthetic receptors, have shown striking efficacy in certain haematological malignancies. Complementary approaches include tumour-infiltrating lymphocyte (TIL) therapy, T cell receptor (TCR) transgenic T cells, and combination regimens that integrate checkpoint inhibitors with cellular therapies. While impressive remissions have been achieved, challenges remain: antigen escape, on-target off-tumour toxicity, T cell exhaustion within the hostile tumour microenvironment and limited efficacy against solid tumours. Ongoing innovations in receptor design, selective targeting, early-line combination therapies and modulation of the tumour milieu aim to extend benefits across a broader spectrum of cancers worldwide.

Research from Nature Portfolio

Recent studies have defined NR2F6 as a non-redundant intracellular checkpoint in effector T cells. Genetic ablation of NR2F6 enhances T cell responsiveness and, when combined with PD-1 or PD-L1 blockade, significantly delays tumour progression in preclinical models. Transcriptional profiling of intratumoral T lymphocytes reveals that NR2F6 deficiency unleashes favourable cytokine programmes, potentiating cytotoxicity without exacerbating systemic toxicity. This work has established a new class of intracellular targets to augment existing checkpoint therapies and lays the groundwork for clinical validation of NR2F6 inhibitors in next-generation immuno-oncology regimens.

T Cell Immunotherapy in Cancer Treatment publication trend

The graph below shows the total number of articles in t cell immunotherapy in cancer treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Adoptive cell transfer: A procedure in which T cells are isolated, expanded or engineered ex vivo and then reinfused into the patient to mediate tumour destruction.

Chimeric antigen receptor (CAR) T cell: A genetically modified T lymphocyte expressing a synthetic receptor that combines an antigen-binding domain with intracellular signalling motifs for targeted cytotoxicity.

Immune checkpoint: A regulatory pathway in T cells that modulates activation; blockade of checkpoint molecules such as PD-1 or CTLA-4 enhances antitumour immunity.

Tumour microenvironment: The complex milieu of stromal cells, immune cells, vessels and soluble factors surrounding a tumour that influences immune infiltration and therapeutic response.

T cell exhaustion: A dysfunctional state of chronically stimulated T cells characterised by reduced effector function and sustained expression of inhibitory receptors.

References

1. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nature Communications (2018).
2. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduction and Targeted Therapy (2022).
3. Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types. Frontiers in Immunology (2020).